Article
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Cancer research - 15 Apr 2014
Holderfield Matthew, Lorenzana Edward, Weisburd Ben, Lomovasky Lisa, Boussemart Lise, Lacroix Ludovic, Tomasic Gorana, Favre Michel, Vagner Stephan, Robert Caroline, Ghoddusi Majid, Daniel Dylan, Pryer Nancy, McCormick Frank, Stuart Darrin
Abstract excerpt
Treatment with RAF inhibitors such as vemurafenib causes the development of cutaneous squamous cell carcinomas (cSCC) or keratoacanthomas as a side effect in 18% to 30% of patients. It is known that RAF inhibitors activate the mitogen-activated protein kinase (MAPK) pathway and stimulate growth of RAS-mutated cells, possibly accounting for up to 60% of cSCC or keratoacanthoma lesions with RAS mutations, but other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.